Chiropractors in Whitehouse, OH Accepting Medicare
3 Chiropractors found. Showing 1 - 3
 Dr. Michael R Hollerbach, DC Chiropractor Medicare: May Accept Medicare Assignments Practice Location: 10345 Waterville St, Whitehouse, OH 43571 Phone: 419-419-3800 Fax: 419-830-4020 |
 Fallen Timbers Chiropractic, Llc Chiropractor - Sports Physician Medicare: Not Enrolled in Medicare Practice Location: 6901 Providence St, Whitehouse, OH 43571 Phone: 419-877-9919 Fax: 419-877-9977 |
Anthony Wayne Community Chiropractic Llc Chiropractor Medicare: Medicare Enrolled Practice Location: 10345 Waterville St, Whitehouse, OH 43571 Phone: 419-419-3800 |
News Archive
AbbVie's ALIGN study underscores patients' attitudes and adherence toward TNF inhibitors
AbbVie today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy.
New study analyses presence of added sugars, sweeteners in spanish foods
In the midst of the war against sugar, Spanish researchers have examined the main food groups that contribute to its consumption, such as soft drinks, yoghurts, chocolates, ice creams, cereals and jams.
Omthera reaches agreement with FDA on SPA for Epanova Phase III trial in patients with very high triglycerides
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the design of its planned Phase III registration clinical trial of Epanova™, the Company's lead compound for the treatment of patients with very high triglycerides. Epanova is an Omega 3 fatty acid containing a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
FDA approves Teva's sNDA for three-times-a-week COPAXONE 40mg/mL
Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved the Company's supplemental new drug application for three-times-a-week COPAXONE 40mg/mL, a new dose of COPAXONE.
› Verified 8 days ago
Physical Therapists
Chiropractors
Speech-Language Pathologists
Optometrists
Occupational Therapists